We evaluated for the first time, to our knowledge, adverse health outcomes (AHOs) among US testicular cancer survivors (TCS) given chemotherapy (n ¼ 381) vs surgery-only patients (n ¼ 98) managed at a single institution, accounting for nontreatment-related risk factors to delineate chemotherapy's impact. Chemotherapy consisted largely of bleomycin-etoposidecisplatin (BEP) administered in three or four cycles (BEPx3, n ¼ 235; BEPx4, n ¼ 82). Incidence of at least 3 AHOs was lowest in surgery-only TCS and increased with BEPx3, BEPx4, and other cisplatin-based regimens (12.2%, 40.8%, 52.5%, 54.8%; P < .0001). Multivariable modeling assessed associations of risk factors and treatment with hearing impairment, tinnitus, peripheral neuropathy, and Raynaud phenomenon. Risk for each AHO statistically increased with both increasing chemotherapy burden (P < .0001) and selected modifiable risk factors (P < .05): hypertension (odds ratio [OR] ¼ 2.40) and noise exposure (OR 2.3) for hearing impairment; noise exposure for tinnitus (OR 1.69); peripheral vascular disease for neuropathy (OR ¼ 8.72); and current smoking for Raynaud phenomenon (OR ¼ 2.41). Clinicians should manage modifiable risk factors for AHOs among TCS.
Testicular cancer is the most common cancer in men aged 18-39 years (1) . Since cisplatin-based chemotherapy was introduced in the 1970s (2) , the overall 5-year relative survival rate is over 95% (3) . As a result, 1 in 600 US men is a testicular cancer survivor (TCS), representing a growing need to evaluate the subsequent development of adverse health outcomes (AHOs). Nonetheless, the few single-institution investigations of US TCS (4-8) have been limited in scope, generally either not addressing AHOs (5, 7, 8) or evaluating fewer than five conditions (6) . Additionally, only Oh et al. (6) included a control group of TCS managed with surgical approaches alone but examined only four AHOs.
In view of these gaps, our goal was to study AHOs among US TCS after contemporary cisplatin-based chemotherapy compared with a surgery-only cohort. The study was institutional review board-approved at Indiana University. Eligible TCS had a histologic or serological germ cell tumor diagnosis at 55 years or younger; all administered treatment and management was completed at least 1 year before enrollment. All participants were disease-free at routine follow-up and completed AHO-focused health questionnaires. AHO definitions and statistical methods are provided in the Supplementary Methods (available online). Two-sided P < .05 defined statistical significance.
Overall, 479 patients were evaluated (Table 1) . Chemotherapy (n ¼ 381) consisted largely of three or four cycles of bleomycin, etoposide, and cisplatin (BEPx3, n ¼ 235; BEPx4, n ¼ 82), with 64 patients receiving other cisplatin-based chemotherapy regimens (Other Plat). Median cumulative cisplatin doses were 300 mg/m 2 (BEPx3) and 400 mg/m 2 (BEPx4 and Other Plat). A total of 98 patients were managed only surgically. No patient received radiotherapy. Median age at evaluation (overall ¼ 38.3 years) and median time since chemotherapy or surgery completion (overall ¼ 4.1 years) were similar between groups. Surgery-only patients had a smaller percentage of nonseminomatous histology compared with chemotherapy-treated TCS receiving BEPx3, BEPx4, and Other Plat (43.3% vs 77.6%, 92.6%, 77.0%, respectively; P < .0001) and were more likely to have primary testicular germ cell tumor (100% vs 88.4%, 67.9%, 63.9%, respectively; P < .0001). Other clinical characteristics, physical examination results, and health behaviors were similar between groups, but more surgery-only TCS reported the absence of noise exposure than did chemotherapy-treated TCS (61.2% vs 51.1%, 37.5%, 43.5%, respectively; P ¼ .0073). The median number of AHOs increased from 1 (range ¼ 0-11) after surgery-only to 2 (range ¼ 0-10) after BEPx3 and 3 (range ¼ 0-9) after BEPx4 and Other Plat. Fewer TCS had at least 3 AHOs after surgery-only (12.2%) than after BEPx3 (40.8%), BEPx4 (52.5%), and Other Plat (54.8%) (P < .0001). Significant differences between surgery-only, BEPx3, BEPx4, and Other Plat were observed for the following AHOs (each P < .05): hearing impairment (11.5%, 36.0%, 41.8%, 45.9%); tinnitus (16.3%, 39.3%, 43.9%, 50.0%); peripheral neuropathy (4.1%, 27.8%, 33.8%, 46.9%); hypertension (0%, 15.7%, 15.0%, 15.0%); Raynaud phenomenon (2.0%, 20.3%, 29.6%, 20.6%); and balance/vertigo/ dizziness (6.1%, 11.0%, 19.5%, 14.3%). For cardiovascular disease (CVD), differences were of borderline significance (1.0%, 5.6%, 9.9%, 7.9%; P ¼ .0648). Table 2 shows the results of multivariable modeling for selected AHOs. TCS given BEPx3, BEPx4, and Other Plat experienced significant tinnitus excesses (odds ratio [OR] ¼ 3.0, 3.71, and 3.99 [P ¼ .0005 each]), with risk increased by 1.44-fold (P < .0001) for each 100 mg/m 2 of cisplatin. Prior work-related (OR ¼ 1.69, P ¼ .0426), non-work-related (OR ¼ 2.1, P ¼ .0399), and cumulative (OR ¼ 2.13, P ¼ .0078) noise exposures were associated with statistically increased twofold tinnitus risks, but no interaction with cisplatin dose existed (P ¼ .5892).
Hearing loss increased statistically with increasing age at clinical evaluation (OR ¼ 1.16 per 5 years, P ¼ .0259), hypertension (OR ¼ 2.40, P ¼ .0101), and in each chemotherapy group (P < .01 each). With each 100-mg/m 2 increase in cisplatin, hearing loss increased by 1.4-fold (P ¼ .0002). Work-related (OR ¼ 2.30, P ¼ .0033), non-work-related (OR ¼ 3.64, P ¼ .0009), and cumulative (OR ¼ 2.75, P ¼ .0012) noise exposures conferred increased hearing loss, but no interaction with cisplatin dose existed (P ¼ .3672).
Raynaud phenomenon was increased 12-fold (P ¼ .0009) and 21-fold (P < .0001) following BEPx3 and BEPx4, respectively, and 12-fold after Other Plat (P ¼ .0018). Risk increased with increasing bleomycin dose (OR ¼ 1.36 per 90 000 IU, P ¼ .0016). Current smoking was associated with statistically increased 2.4-fold risks.
Peripheral neuropathy was increased by 9-, 13-, and 18-fold, respectively, after BEPx3, BEPx4, and Other Plat (P < .0001 each). Increasing age at assessment (OR ¼ 1.23 per 5 years, P ¼ .0033), higher cumulative cisplatin dose (OR ¼ 1.75 per 100 mg/m 2 , P < .0001), and peripheral vascular disease (OR ¼ 8.72, P ¼ .0010) were associated with higher neuropathy risks.
Our study investigates for the first time, to our knowledge, the prevalence and risk factors for chemotherapy-related AHOs in US TCS with surgery-only patients as the control group. We took into account previously identified AHO-specific risk factors, thus furthering our understanding of the specific impact of chemotherapy. Risk of treatment-related AHOs increased proportionately with increasing chemotherapy burden. Importantly, modifiable risk factors were also associated with AHOs even when controlled for chemotherapy.
It is noteworthy that even after a short median follow-up, about 1 in 7 TCS in each chemotherapy group had hypertension compared with no cases after surgery-only (P ¼ .0007). A similar trend of borderline significance was noted for CVD.
Major strengths of our study are that all TCS were managed at one large, well-established US institution. However, AHOs were largely self-reported without baseline data pretherapy. Cross-sectional designs have potential inherent limitations and do not permit causal inference, although prospective follow-up is planned. Although the control group (surgery-only patients) had a lower disease burden initially than did chemotherapytreated TCS, no TCS had active disease at the time of study enrollment. We cannot rule out, however, any potential influence of initial disease burden on AHO development.
Nonetheless, we provide for the first time, to our knowledge, estimates of the magnitude of AHOs associated with current chemotherapy in US TCS compared with surgery-only patients. This may potentially guide clinical decision-making, such as recommending surgical approaches with primary retroperitoneal lymph node dissection in patients with low-bulk stage II disease in an attempt to avoid chemotherapy-related AHOs. Future studies should address AHO incidence when adjuvant chemotherapy is applied in early-stage disease or in guiding decisions regarding primary retroperitoneal lymph node dissection vs chemotherapy in early stage II disease.
The incidence of several AHOs (eg, hypertension, CVD) will likely increase with the aging process (9) . Thus, patients should be encouraged to adopt practices consistent with a healthy lifestyle and avoid noise exposure, ototoxic drugs, and other factors that may further affect AHOs. Health-care providers should diligently manage comorbidities to minimize the development or exacerbation of AHOs.
